Trial · NCT07397832
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
NCT07397832, Phase 2, Recruiting, Tianjin Medical University Cancer Institute and Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL. Trials, record NCT07397832. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07397832
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
- NCT number
- NCT07397832
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 58 participants, estimated
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Chidamide, Rituximab, Polatuzumab Vedotin, Chidamide Maintenance
- First posted
- 2026-02-09
- Last updated
- 2026-07-29
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response Rate (CRR) | up to the end of CRP Regimen treatment, no more than 6 cycles, each cycle is 21 days | To assess the Complete Response Rate (CR) at the end of CRP Regimen (Chidamide, Rituximab, Polatuzumab Vedotin). |
| Secondary | Overall Response Rate (ORR) | up to the end of CRP Regimen treatment, no more than 6 cycles, each cycle is 21 days | To assess the Overall Response Rate (ORR) at the end of CRP Regimen (Chidamide, Rituximab, Polatuzumab Vedotin). |
| Secondary | Progression-free survival (PFS) | up to 2 years | The time from study enrollment to the first documented disease progression or death from any cause, whichever occurs first." |
| Secondary | Event free survival(EFS) | up to 2 years | The duration from the time of study enrollment until the occurrence of disease progression, relapse after complete response (CR), death from any cause, or the initiation of new treatment for residual lesions after completion of combination therapy (including switched therapy for lesions during the trial), whichever occurs first. |
| Secondary | Overall Survival(OS) | up to 2 years | The time from subject enrollment to Death caused by any reason. for patients lost to follow-up, the time of the last follow-up; for patients still alive at the end of study, the date of the end of follow-up. |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | up to 2 years | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.The frequency and severity of adverse events were evaluated based on changes in various vital sign indicators and laboratory tests. |
| Secondary | Quality of Life Assessment - EORTC QLQ-C30 Score | up to 2 years | Quality of life will be assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The score changes in overall quality of life, functional scales, and symptom scales will be analyzed in relation to clinical outcomes. |
| Secondary | Quality of Life Assessment - FACT-Lym Score | up to 2 years | Disease-specific quality of life will be assessed using the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) questionnaire (Version 4). The score changes will be analyzed in relation to clinical outcomes. |
| Other | Biomarkers Associated with Treatment Response and Disease Progression | up to 2 years | Using Whole Transcriptome Sequencing (WTS) and Next-Generation Sequencing (NGS), we will examine if baseline molecular/proteomic subtypes, genomic profiles, and specific somatic mutations affect CRP regimen efficacy or drive disease progression to more severe states. |
| Other | Biomarkers Associated with Adverse Events | up to 2 years | We will use Whole Transcriptome Sequencing (WTS) and NGS to investigate whether specific somatic mutations increase the risk of CRP regimen-related adverse events. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07397832
GET https://conductscience.org/api/trials/v1/NCT07397832/registered